We are live on
!
Find out more
FAM
Fred Alger Management Portfolio holdings
AUM
$22.8B
1-Year Est. Return
64.63%
This Fund
S&P 500
This Quarter
Est. Return
-8.41%
1 Year Est. Return
+64.63%
3 Year Est. Return
+243.99%
5 Year Est. Return
+318.3%
10 Year Est. Return
+1,899.64%
AUM
$22.8B
AUM Growth
-$4.41B
(-16%)
Cap. Flow
-$1.27B
Cap. Flow
% of AUM
-5.6%
Top 10 Holdings %
Top 10 Hldgs %
36.84%
Holding
614
New
135
Increased
158
Reduced
239
Closed
65
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$190M |
| 2 |
Lowe's Companies
LOW
|
+$187M |
| 3 |
Netflix
NFLX
|
+$179M |
| 4 |
Starbucks
SBUX
|
+$114M |
| 5 |
Novartis
NVS
|
+$92.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$260M |
| 2 |
Microsoft
MSFT
|
+$208M |
| 3 |
Salesforce
CRM
|
+$171M |
| 4 |
Dollar Tree
DLTR
|
+$171M |
| 5 |
Adobe
ADBE
|
+$151M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.16% |
| 2 | Healthcare | 22.78% |
| 3 | Consumer Discretionary | 14.09% |
| 4 | Communication Services | 9.78% |
| 5 | Financials | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DCPH
401
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $165K | ﹤0.01% |
4,000
-14,000
| -78% | -$777K |
|
|
TRIL
402
DELISTED
Trillium Therapeutics Inc.
TRIL
| $162K | ﹤0.01% |
+40,000
| New | +$151K |
|
403
Diamondback Energy
FANG
$57.1B
| $158K | ﹤0.01% |
+6,034
| New | +$380K |
|
|
APLS
404
DELISTED
Apellis Pharmaceuticals
APLS
| $134K | ﹤0.01% |
5,000
-10,000
| -67% | -$355K |
|
|
CBIO
405
Crescent Biopharma
CBIO
$537M
| $125K | ﹤0.01% |
550
-50
| -8% | -$19.1K |
|
406
PVH
PVH
$4B
| $122K | ﹤0.01% |
3,250
| – | – |
|
|
FPRX
407
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $114K | ﹤0.01% |
50,000
| – | – |
|
408
T. Rowe Price
TROW
$23.9B
| $78K | ﹤0.01% |
797
+113
| +17% | +$13.8K |
|
|
CLSD
409
DELISTED
Clearside Biomedical
CLSD
| $68K | ﹤0.01% |
2,667
+667
| +33% | +$24.7K |
|
410
Brown-Forman Class B
BF.B
$13.2B
| $66K | ﹤0.01% |
1,193
+723
| +154% | +$46.5K |
|
|
PRVB
411
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $64K | ﹤0.01% |
+7,000
| New | +$90.2K |
|
|
MRSH
412
Marsh
MRSH
$90.5B
| $63K | ﹤0.01% |
731
+434
| +146% | +$46.3K |
|
413
McKesson
MCK
$100B
| $62K | ﹤0.01% |
458
+230
| +101% | +$33.7K |
|
414
Cue Biopharma
CUE
$113M
| $57K | ﹤0.01% |
+133
| New | +$64.5K |
|
415
iShares Russell 2000 Growth ETF
IWO
$14.3B
| $57K | ﹤0.01% |
363
-17,152
| -98% | -$3.41M |
|
416
Nordson
NDSN
$16.6B
| $56K | ﹤0.01% |
417
+323
| +344% | +$49.7K |
|
417
Trane Technologies
TT
$100B
| $53K | ﹤0.01% |
636
+142
| +29% | +$17.2K |
|
418
Crown Holdings
CCK
$12.8B
| $51K | ﹤0.01% |
877
-270
| -24% | -$18.8K |
|
419
Skyworks Solutions
SWKS
$9.37B
| $51K | ﹤0.01% |
566
-585
| -51% | -$62.5K |
|
420
Labcorp
LH
$25B
| $49K | ﹤0.01% |
450
+22
| +5% | +$3.17K |
|
421
Lockheed Martin
LMT
$134B
| $43K | ﹤0.01% |
127
+43
| +51% | +$16.9K |
|
|
FLNA
422
Filana Therapeutics
FLNA
$48.8M
| $41K | ﹤0.01% |
+10,000
| New | +$66.2K |
|
423
Carlisle Companies
CSL
$14.3B
| $37K | ﹤0.01% |
297
+93
| +46% | +$13.8K |
|
424
WIX.com
WIX
$2.3B
| $36K | ﹤0.01% |
355
-281
| -44% | -$36.7K |
|
425
CDW
CDW
$18.9B
| $32K | ﹤0.01% |
344
-7,312
| -96% | -$895K |
|
Similar funds
CAM
BA
AM
SAM
CHP
Fred Alger Management's Q1 2020 Portfolio in Review
As of Q1 2020, Fred Alger Management held 614 positions worth $22.8B, down 16% from $27.2B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Fred Alger Management withdrew a net $1.27B in Q1 2020, closing 65 positions and reducing 239 holdings. Its most notable exit was Dermira, Inc., an estimated $46.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Fred Alger Management opened a new position in AtriCure worth $42.4M.
- Fred Alger Management's largest Q1 2020 buy was AtriCure: 1,263,408 shares worth $42.4M.
- Fred Alger Management added most to NVIDIA in Q1 2020, an estimated $190M increase.
- Fred Alger Management's biggest Q1 2020 reduction was Abbott, cutting an estimated $260M.
- Fred Alger Management fully exited Dermira, Inc. in Q1 2020, selling an estimated $46.3M.
- Fred Alger Management's ten largest holdings make up 37% of its $22.8B portfolio in Q1 2020.
- Fred Alger Management opened 135 new positions and closed 65 in Q1 2020.
- Fred Alger Management's portfolio value fell 16% quarter-over-quarter to $22.8B.
Based on Fred Alger Management's 13F filing for Q1 2020, filed 15 May 2020.